Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
J Med Life ; 14(4): 431-442, 2021.
Article in English | MEDLINE | ID: covidwho-1464171


Since December 2019, the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has been a global health concern. The transmission method is human-to-human. Since this second wave of SARS-CoV-2 is more aggressive than the first wave, rapid testing is warranted to use practical diagnostics to break the transfer chain. Currently, various techniques are used to diagnose SARS-CoV-2 infection, each with its own set of advantages and disadvantages. A full review of online databases such as PubMed, EMBASE, Web of Science, and Google Scholar was analyzed to identify relevant articles focusing on SARS-CoV-2 and diagnosis and therapeutics. The most recent article search was on May 10, 2021. We summarize promising methods for detecting the novel Coronavirus using sensor-based diagnostic technologies that are sensitive, cost-effective, and simple to use at the point of care. This includes loop-mediated isothermal amplification and several laboratory protocols for confirming suspected 2019-nCoV cases, as well as studies with non-commercial laboratory protocols based on real-time reverse transcription-polymerase chain reaction and a field-effect transistor-based bio-sensing device. We discuss a potential discovery that could lead to the mass and targeted SARS-CoV-2 detection needed to manage the COVID-19 pandemic through infection succession and timely therapy.

COVID-19 , SARS-CoV-2 , COVID-19/diagnosis , COVID-19 Testing , Humans , Molecular Diagnostic Techniques , Nucleic Acid Amplification Techniques , Pandemics , SARS-CoV-2/isolation & purification , Sensitivity and Specificity
Mater Today Proc ; 46: 11098-11102, 2021.
Article in English | MEDLINE | ID: covidwho-1096154


COVID-19 is the present-day pandemic around the globe. WHO has estimated that approx 15% of the world's population may have been infected with coronavirus with a large number of population on the verge of being infected. It is quite difficult to break the virus chain since asymptomatic patients can result in the spreading of the infection apart from the seriously infected patients. COVID-19 has many similar symptoms to SARS-D however, the symptoms can worsen depending on the immunity power of the patients. It is necessary to be able to find the infected patients even with no symptoms to be able to break the spread of the chain. In this paper, the comparison table describes the accuracy of deep learning architectures by the implementation of different optimizers with different learning rates. In order to remove the overfitting issue, different learning rate has been experimented. Further in this paper, we have proposed the classification of the COVID-19 images using the ensemble of 2 layered Convolutional Neural Network with the Transfer learning method which consumed lesser time for classification and attained an accuracy of nearly 90.45%.

Biomed J ; 43(5): 424-433, 2020 10.
Article in English | MEDLINE | ID: covidwho-679602


Coronavirus disease 2019 (COVID-19) is a major public health concern currently. To date, there are no approved antiviral drugs or vaccines against this transmissible disease. This report sheds light on available information for a better understanding of clinical trials and pharmacotherapy related to COVID-19. MEDLINE, PubMed, EMBASE, Scopus databases, Web of Science, WHO, and EU clinical trial sites were used to perform comparative analysis. Information was collected on the use of therapeutic agents for human therapy in patients with COVID-19 up to May 2020. We have extracted data from 60 clinical trials. Amongst these trials, 34 were from the European Union database of clinical trials and 26 from the National Institute of Health. The data selection procedure includes active, completed, and recruitment in progress status. Most of the clinical trials are ongoing and hence, there is a lack of precise results for the treatment.There is a lack of high-quality clinical evidence. The protocol to be developed requires large randomized clinical trials with a combination of available drugs and prospective therapies. We propose the usage of a large number of cases and different statistical analyses to conduct systematic clinical trials. This could provide comprehensive information about the clinical trial and potential therapeutic progress.

COVID-19/drug therapy , Clinical Trials as Topic , SARS-CoV-2/drug effects , COVID-19/virology , Europe , Humans , SARS-CoV-2/pathogenicity , World Health Organization